Patents by Inventor Raghavan Rajagopalan

Raghavan Rajagopalan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7303926
    Abstract: The present invention discloses dye-azide derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and nitrene at the lesion of interest.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: December 4, 2007
    Assignee: Mallinckrodt, Inc
    Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
  • Publication number: 20070269368
    Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
    Type: Application
    Filed: July 16, 2007
    Publication date: November 22, 2007
    Applicant: MALLINCKRODT, INC.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard Dorshow, Joseph Bugaj, Muthunadar Periasamy
  • Publication number: 20070269373
    Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
    Type: Application
    Filed: July 16, 2007
    Publication date: November 22, 2007
    Applicant: MALLINCKRODT, INC.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard Dorshow, Joseph Bugaj, Muthunadar Periasamy
  • Patent number: 7297325
    Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: November 20, 2007
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
  • Patent number: 7294738
    Abstract: The present invention discloses novel steroid mimics wherein a tri- or tetravalent phosphorous atom is isosterically substituted at any one of the seventeen positions occupied by the carbon atom in the steroidal skeleton, and wherein each adjacent position to the phosphorous is either unsubstituted or optionally substituted by nitrogen or an oxygen atom to satisfy the valency of said phosphorous atom. The invention is illustrated schematically below using both aromatic and non-aromatic steroids. Although the isosteric substitution phosphorous atom in the above structures 3–7 is indicated at 13, 14, and 17 positions, it is to be noted that the phosphorous can be substituted at any one of the seventeen positions in non-aromatic or eleven positions in aromatic steroids. The phosphorous atom may be trivalent or tetravalent, and may be radioactive or non-radioactive. The adjacent atoms, X, Y, or Z may be carbon, oxygen, or nitrogen.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: November 13, 2007
    Inventor: Raghavan Rajagopalan
  • Patent number: 7252815
    Abstract: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: August 7, 2007
    Assignee: Mallinckrodt, Inc.
    Inventors: Samuel Achilefu, Richard B. Dorshow, Raghavan Rajagopalan, Joseph E. Bugaj
  • Patent number: 7235685
    Abstract: The present invention discloses novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photofragmentation of the sulfenate moiety, with the tissue of interest.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: June 26, 2007
    Assignee: Mallinckrodt, Inc.
    Inventors: Raghavan Rajagopalan, Gary L. Cantrell, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
  • Patent number: 7230088
    Abstract: The invention discloses compounds and compositions for dual phototherapy and combined therapy and diagnosis of tumors and other lesions. The compounds have a Dye that, when photoactivated, operates via Type I and/or Type II mechanisms. Other Dye or azide components may operate by the same or different mechanisms. Selection of particular components in a compound, and formulation of the compound(s) in a composition permit different activation wavelengths to be used for different therapies. A targeting moiety may be added to the compound or composition so that the Dye locates at a particular site, such as a hormone-sensitive tumor, for diagnosis and/or treatment. The compounds and compositions may be incorporated within liposomes.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: June 12, 2007
    Assignee: Mallinckrodt, Inc.
    Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow, Muthunadar P. Periasamy
  • Publication number: 20070128115
    Abstract: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.
    Type: Application
    Filed: March 24, 2006
    Publication date: June 7, 2007
    Inventors: Samuel Achilefu, Richard Dorshow, Raghavan Rajagopalan, Joseph Bugaj
  • Publication number: 20070092450
    Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
    Type: Application
    Filed: December 7, 2006
    Publication date: April 26, 2007
    Applicant: MALLINCKRODT INC.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard Dorshow, Joseph Bugaj
  • Patent number: 7201892
    Abstract: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: April 10, 2007
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel Achilefu, Richard B. Dorshow, Raghavan Rajagopalan, Joseph E. Bugaj
  • Patent number: 7198778
    Abstract: Cyanine dye bioconjugates useful for diagnostic imaging and therapy are disclosed. The conjugates include several cyanine dyes with a variety of bis- and tetrakis (carboxylic acid) homologs. The compounds may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of the compounds allows more favorable delivery to tumor cells as compared to larger molecular weight imaging agents. The various dyes are useful over the range of 350 to 1300 nm, the exact range being dependent upon the particular dye. The use of dimethylsulfoxide helps to maintain the fluorescence of the compounds. The inventive compounds are useful for diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluoresence tumor imaging, detection and therapy.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: April 3, 2007
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel I. Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
  • Patent number: 7175831
    Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
    Type: Grant
    Filed: January 2, 2004
    Date of Patent: February 13, 2007
    Assignee: Mallinckrodt, Inc.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Hermo N. Jimenez, Muthunadar P. Periasamy
  • Patent number: 7128896
    Abstract: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: October 31, 2006
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel Achilefu, Richard B. Dorshow, Raghavan Rajagopalan, Joseph E. Bugaj
  • Publication number: 20060177457
    Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.
    Type: Application
    Filed: March 21, 2006
    Publication date: August 10, 2006
    Applicant: Mallinckrodt Inc.
    Inventors: Raghavan Rajagopalan, Samuel Achilefu, Joseph Bugaj, Richard Dorshow
  • Publication number: 20060106070
    Abstract: This invention relates to novel pyridine-based divalent metal ion chelating ligands of Formula I, wherein A or B are independently —R6R7, or —CH(R8)CH(R9). R1 to R9 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics. The compounds of the present invention are useful for inhibiting the activity of viral enzymes responsible for the proliferation of human immunodeficiency virus (HIV).
    Type: Application
    Filed: October 27, 2005
    Publication date: May 18, 2006
    Applicant: Bioflexis, LLC
    Inventors: Raghavan Rajagopalan, John Babu
  • Publication number: 20060100282
    Abstract: This invention relates to novel diaminopropane-based divalent metal ion chelating ligands of Formula I, wherein A is selected from the group consisting of —(CH2)a—, —(CH2)bO(CH2)c—, —(CH2O)d—, and —(CH2)eN(R4)(CH2)f—; a and c vary from 0 to 10; b, e, and f vary from 2 to 10, and d varies from 1 to 10. X and Y are independently —CR5R6, or —CH(R7)CH(R8). R1 to R8 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 13. R1 to R8 may include, but are not limited to hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, substituted or unsubstituted aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, halogen, alkoxycarbonyl, cyano, and other suitable electron donating or electron withdrawing groups. Ar may unsubstituted phenyl group or may be substituted with suitable electron donating or electron withdrawing groups.
    Type: Application
    Filed: October 27, 2005
    Publication date: May 11, 2006
    Applicant: Bioflexis, LLC
    Inventors: Raghavan Rajagopalan, John Babu
  • Publication number: 20060094755
    Abstract: This invention relates to novel quinoline-based divalent metal ion chelating ligands of Formula I, wherein A or B are independently —CR7R8, or —CH(R9)CH(R10). X is hydrogen, C1-C10 alkyl; —OH, or —NR11R12. R1 to R12 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 13. R1 to R12 may include, but are not limited to hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, substituted or unsubstituted aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, halogen, alkoxycarbonyl, cyano, and other suitable electron donating or electron withdrawing groups. The compounds of the present invention are useful for inhibiting the activity of viral enzymes responsible for the proliferation of human immunodeficiency virus (HIV).
    Type: Application
    Filed: October 27, 2005
    Publication date: May 4, 2006
    Applicant: Bioflexis, LLC
    Inventors: Raghavan Rajagopalan, John Babu
  • Patent number: 7011817
    Abstract: Cyanine dye bioconjugates useful for diagnostic imaging and therapy are disclosed. The conjugates include several cyanine dyes with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of the compounds allows more favorable delivery to tumor cells as compared to larger molecular weight imaging agents. The various dyes are useful over the range of 350-1300 nm, the exact range being dependent upon the particular dye. Use of dimethylsulfoxide helps to maintain the fluorescence of the compounds. The inventive compounds are useful for diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: March 14, 2006
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel I. Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj
  • Publication number: 20060035883
    Abstract: The present invention discloses novel 5-HT receptor binding agents of Formula 3, wherein X is —CH or —N—. Y is selected from the group consisting of —CR10R11, —NR12, —O—, —S—, —SO—, and —SO2—. R1 to R12 are various substituents selected to optimize the physicochemical and biological properties such as receptor binding, receptor selectivity, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 3. These include hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, alkoxycarbonyl, halogen, cyano, and other suitable electron donating or electron withdrawing groups. R2 and R3, R3 and R4, or R5 and R6 may optionally be tethered together to form fused alicyclic or heterocyclic ring. R1 and R2, R4 and R5, or R6 and R7 may also optionally be tethered together to form spiro carbo- or heterocyclic ring.
    Type: Application
    Filed: August 12, 2005
    Publication date: February 16, 2006
    Inventors: Clark Tedford, Raghavan Rajagopalan